Oncology Clinical Trials in New Haven, CT

As of September 2026, 212 paid clinical trials are recruiting for Oncology in New Haven, Connecticut. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: September 1, 2026.

Filter results

State

City

Facility

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

214 clinical trials for Oncology

·Clear filters·

Email me when a new oncology trial opens in New Haven, CT.

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

for Acute Myeloid Leukemia

Drug: Venetoclax

Sites in New Haven +43 more locations

Sponsor: Kura Oncology, Inc.

Sex: All·Age: 18+

Code: NCT05735184·Phase 1·Recruiting·Listed Feb 2023

Apply to this trial

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

for Advanced Solid Tumor

Sites in New Haven +30 more locations

Sponsor: PMV Pharmaceuticals, Inc

Sex: All·Age: 12+

Code: NCT04585750·Phase 1, Phase 2·Recruiting·Listed Oct 2020

Apply to this trial

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

for Epithelial Ovarian Cancer

Sites in New Haven +25 more locations

Sponsor: TORL Biotherapeutics, LLC

Sex: Female·Age: 18+

Code: NCT06690775·Phase 2·Recruiting·Listed Nov 2024

Apply to this trial

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

for Glioblastoma (GBM)

Sites in New Haven +27 more locations

Sponsor: Black Diamond Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07326566·Phase 2·Recruiting·Listed Jan 2026

Apply to this trial

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

for Clear Cell Renal Cell Carcinoma

Sites in New Haven +11 more locations

Sponsor: Neomorph, Inc

Sex: All·Age: 18+

Code: NCT07300241·Phase 1·Recruiting·Listed Dec 2025

Apply to this trial

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

for Bladder Cancer

Sites in New Haven +14 more locations

Sponsor: EvolveImmune United, Inc

Sex: All·Age: 18+

Code: NCT07217171·Phase 1·Recruiting·Listed Oct 2025

Apply to this trial

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

for Lymphoma, Non-Hodgkin

Sites in New Haven +22 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07101328·Phase 1·Recruiting·Listed Aug 2025

Apply to this trial

A Study of PHST001 in Advanced Solid Tumors

for Advanced Solid Tumors

Sites in New Haven +19 more locations

Sponsor: Pheast Therapeutics

Sex: All·Age: 18+

Code: NCT06840886·Phase 1·Recruiting·Listed Feb 2025

Apply to this trial

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

for Gastric Cancer

Sites in New Haven +14 more locations

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06731478·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

for Small Cell Lung Cancer

Drug: Atezolizumab

Sites in New Haven +10 more locations

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT07155174·Phase 2·Recruiting·Listed Sep 2025

Apply to this trial

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

for Advanced/Metastatic Solid Tumors

Sites in New Haven, Trumbull +19 more locations

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07090499·Phase 1·Recruiting·Listed Jul 2025

Apply to this trial

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

for Lymphoma

Drug: Glofitamab

Sites in New Haven +19 more locations

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06084936·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

for Solid Malignancies

Sites in New Haven +18 more locations

Sponsor: Immunome, Inc.

Sex: All·Age: 18+

Code: NCT06823167·Phase 1·Recruiting·Listed Feb 2025

Apply to this trial

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

for Non-Small Cell Lung Cancer

Drug: Divarasib

Sites in New Haven +10 more locations

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT05789082·Phase 1, Phase 2·Recruiting·Listed Mar 2023

Apply to this trial

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

for Advanced Solid Tumor

Sites in New Haven, Hartford +16 more locations

Sponsor: BioNTech SE

Sex: All·Age: 18+

Code: NCT07070232·Phase 1, Phase 2·Recruiting·Listed Jul 2025

Apply to this trial

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

for Metastatic Colorectal Cancer

Drug: Bevacizumab

Sites in New Haven +16 more locations

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT06820463·Phase 2·Recruiting·Listed Feb 2025

Apply to this trial

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

for Myelodysplastic Syndromes

Sites in New Haven +21 more locations

Sponsor: Takeda

Sex: All·Age: 18+

Code: NCT06499285·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

for Metastatic Prostate Cancer

Sites in New Haven +16 more locations

Sponsor: Janssen Research & Development, LLC

Sex: Male·Age: 18+

Code: NCT06800313·Phase 1, Phase 2·Recruiting·Listed Jan 2025

Apply to this trial

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

for Carcinoma, Non-Small-Cell Lung

Sites in New Haven, Farmington +16 more locations

Sponsor: Johnson & Johnson Enterprise Innovation Inc.

Sex: All·Age: 18+

Code: NCT06667908·Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

for Metastatic Castration-Resistant Prostate Cancer

Sites in New Haven +22 more locations

Sponsor: Kyntra Bio

Sex: Male·Age: 18+

Code: NCT06842498·Phase 2·Recruiting·Listed Feb 2025

Apply to this trial

A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

for Solid Tumor

Sites in New Haven +10 more locations

Sponsor: Exelixis

Sex: All·Age: 18+

Code: NCT06952010·Phase 1·Recruiting·Listed Apr 2025

Apply to this trial

A Study of ASP1002 in Adults for Treatment of Solid Tumors

for Advanced Solid Tumors

Sites in New Haven, Plainville +10 more locations

Sponsor: Astellas Pharma Global Development, Inc.

Sex: All·Age: 18+

Code: NCT05719558·Phase 1·Recruiting·Listed Feb 2023

Apply to this trial

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

for Advanced Solid Tumor

Sites in New Haven +11 more locations

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06172478·Phase 2·Recruiting·Listed Dec 2023

Apply to this trial

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

for B-cell Acute Lymphoblastic Leukemia

Sites in New Haven +16 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 6 Months - 25

Code: NCT06395103·Phase 1, Phase 2·Recruiting·Listed May 2024

Apply to this trial

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

for Solid Tumor

Sites in New Haven +10 more locations

Sponsor: Genentech, Inc.

Sex: All·Age: 18+

Code: NCT06619587·Phase 1·Recruiting·Listed Oct 2024

Apply to this trial

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

for SST2-positive Neuroendocrine Neoplasms

Sites in New Haven +22 more locations

Sponsor: Crinetics Pharmaceuticals Inc.

Sex: All·Age: 18+

Code: NCT07129252·Phase 1, Phase 2·Recruiting·Listed Aug 2025

Apply to this trial

XTX301 in Patients With Advanced Solid Tumors

for Advanced Solid Tumor

Sites in New Haven +9 more locations

Sponsor: Xilio Development, Inc.

Sex: All·Age: 18+

Code: NCT05684965·Phase 1, Phase 2·Recruiting·Listed Jan 2023

Apply to this trial

Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

for Advanced Solid Tumor

Sites in New Haven +13 more locations

Sponsor: Debiopharm International SA

Sex: All·Age: 12+

Code: NCT04855656·Phase 1·Recruiting·Listed Apr 2021

Apply to this trial

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

for Advanced Solid Tumors

Sites in New Haven +9 more locations

Sponsor: Ensem Therapeutics

Sex: All·Age: 18+

Code: NCT06993844·Phase 1, Phase 2·Recruiting·Listed May 2025

Apply to this trial

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

for Multiple Myeloma

Sites in New Haven +10 more locations

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT06953960·Phase 1, Phase 2·Recruiting·Listed May 2025

Apply to this trial

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

for Advanced Solid Tumors

Sites in New Haven +12 more locations

Sponsor: Tubulis GmbH

Sex: All·Age: 18+

Code: NCT06657222·Phase 1, Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

for Advanced Solid Tumor

Sites in New Haven +8 more locations

Sponsor: SillaJen, Inc.

Sex: All·Age: 18+

Code: NCT05768932·Phase 1·Recruiting·Listed Mar 2023

Apply to this trial

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

for Advanced Solid Tumor

Sites in New Haven +13 more locations

Sponsor: Eikon Therapeutics

Sex: All·Age: 18 - 89

Code: NCT06253130·Phase 1, Phase 2·Recruiting·Listed Feb 2024

Apply to this trial

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

for Non-small Cell Lung Cancer (NSCLC)

Sites in New Haven +16 more locations

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT06040541·Phase 1·Recruiting·Listed Sep 2023

Apply to this trial

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

for Non-Small Cell Lung Cancer

Sites in New Haven +15 more locations

Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Sex: All·Age: 18+

Code: NCT06917079·Phase 1·Recruiting·Listed Apr 2025

Apply to this trial

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

for Non-small Cell Lung Cancer

Sites in New Haven, Norwalk +20 more locations

Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Sex: All·Age: 18+

Code: NCT06343402·Phase 1·Recruiting·Listed Apr 2024

Apply to this trial

QTX3034 in Patients With KRAS G12D Mutation

for Solid Tumors

Sites in New Haven +13 more locations

Sponsor: Quanta Therapeutics

Sex: All·Age: 18+

Code: NCT06227377·Phase 1·Recruiting·Listed Jan 2024

Apply to this trial

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer

for Metastatic Castration-resistant Prostate Cancer

Sites in New Haven +12 more locations

Sponsor: Regeneron Pharmaceuticals

Sex: Male·Age: 18+

Code: NCT05125016·Phase 1, Phase 2·Recruiting·Listed Nov 2021

Apply to this trial

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

for Myelodysplastic Syndromes

Drug: Venetoclax

Sites in New Haven +21 more locations

Sponsor: Taiho Oncology, Inc.

Sex: All·Age: 18+

Code: NCT04256317·Phase 2, Phase 3·Recruiting·Listed Feb 2020

Apply to this trial

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

for Advanced or Metastatic Solid Tumors

Sites in New Haven +13 more locations

Sponsor: 858 Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06395519·Phase 1, Phase 2·Recruiting·Listed May 2024

Apply to this trial

Conditions in Oncology (New Haven, CT)

Solid tumor· 59 Non-small cell lung cancer (NSCLC)· 32 Breast cancer· 23 Acute myeloid leukemia (AML)· 15 Cancer (any)· 13 Metastatic breast cancer· 12 Prostate cancer· 12 Ovarian cancer· 11 Head and neck cancer· 11 Endometrial cancer· 10 Colorectal cancer· 9 Gastric cancer· 8 Multiple myeloma· 8 Pancreatic cancer· 7 Esophageal cancer· 7 Metastatic prostate cancer· 7 Myelodysplastic syndromes (MDS)· 7 Hematologic malignancy· 7 Triple-negative breast cancer· 5 HER2-negative breast cancer· 5 Bladder cancer· 5 Cervical cancer· 5 Lung cancer· 4 Kidney cancer· 4 Fallopian tube cancer· 4 Glioma· 4 Leukemia (other)· 4 Non-Hodgkin lymphoma· 4 Diffuse large B-cell lymphoma (DLBCL)· 4 Melanoma· 4 HER2-positive breast cancer· 3 Small cell lung cancer· 3 Metastatic colorectal cancer· 3 Gastroesophageal junction cancer· 3 Biliary tract cancer· 3 Neuroblastoma· 3 Chronic lymphocytic leukemia (CLL)· 2 Chronic myelomonocytic leukemia· 2 Mantle cell lymphoma· 2 Osteosarcoma· 2 Liver cancer· 1 Gastrointestinal cancer· 1 Glioblastoma· 1 Brain cancer· 1 Brain metastases· 1 Acute lymphoblastic leukemia· 1 Myelofibrosis· 1 Myeloproliferative neoplasm· 1 Hodgkin lymphoma· 1 Follicular lymphoma· 1 Marginal zone lymphoma· 1 Small lymphocytic lymphoma· 1 Burkitt lymphoma· 1 Thyroid cancer· 1 Ewing sarcoma· 1 Neuroendocrine tumors· 1